Recombinant adeno-associated virus (AAV) vectors are promising tools for gene therapy. In spinal cord injury where extensive damage occurs, vectors with high diffusion and transduction abilities are required. We compared the diffusion capacity and transduction efficiency of AAV2 and AAV5 vectors using a mouse spinal cord injury model. Our study demonstrates that AAV5 is more effective than AAV2 for delivering genes into the injured spinal cord tissue. AAV5 diffused 6.9 mm from the injection site, transduced with an approximately two-fold increase in total cell number and yielded an approximately three-fold increase in gene expression in comparison with AAV2.
Introduction
Traumatic spinal cord injury is a central nervous system (CNS) lesion that results from blunt or penetrating trauma that causes motor and sensory impairments distal to the injury level. Spinal injury causes severe physical, psychological and economic difficulties for the patients and their families, as unlike in the peripheral nervous system, neurons in the CNS do not regenerate in general [1] . The lack of a developmental program to recapitulate growth in the CNS is primarily because of restrictions on the adult CNS neurons, which prevent these neurons from expressing the genes necessary for neural recovery, and because of the overall nonpermissive properties of the glial scar tissue and CNS myelin [2] .
For several decades, extensive research has focused on promoting regenerative growth of injured axons in the damaged spinal cord. Gene therapy provides one potential treatment to overcome the lack of regenerative ability of the injured neurons and may also be effective in modifying the environment at the injury site by providing factors to promote axonal regrowth. Upregulation of the cyclic AMP signalling pathway [3] , reduction of the activity of the rhoA GTPase [4, 5] , increased levels of the adhesion molecule L1 and of polysialic acid, which is the most conducive neurite outgrowth promoting form of the neural cell adhesion molecule NCAM [6] [7] [8] and delivery of neurotrophins, including neurotrophin-3 [9] and brain-derived neurotrophic factor [10] , are able to promote the regrowth of different types of injured axons.
To deliver molecules capable of modifying the injured parenchyma of the spinal cord from inhibitory to growth promoting, gene therapy vectors based on recombinant adeno-associated virus (AAV) are most promising. Eleven naturally occurring AAV serotypes have been isolated. AAV2, the first serotype to be discovered [11] , has been the most extensively studied in clinical trials [12] . However, other AAV serotypes have proven to be more effective for gene delivery. AAV5, originally identified from a clinical human sample [13] , was considered a promising candidate for use as a gene transfer vector in the CNS [14] . Both the AAV vectors have been used for gene transfer into the spinal cord [8, 15] , but they have not been directly compared in the injured spinal cord.
In this study, we quantified the diffusion capacity and transduction efficiency of AAV2 and AAV5 using a mouse spinal cord injury model. The spinal cord compression model creates a traumatic environment that allows comparing diffusion and transduction properties of the AAV2 and AAV5 vectors that contained the same genome with AAV2 inverted terminal repeats and the enhanced green fluorescent protein (EGFP) reporter gene. Our results demonstrate that AAV5 was more effective than AAV2 in the injured spinal cord in both diffusion and gene transduction, warranting further development of this vector for spinal cord-directed gene therapy approaches.
Materials and methods

Animals
Three-month-old female C57BL/6J mice were purchased from the Guangdong Medical Laboratory Animal Center (People's Republic of China). The animals were maintained under standard conditions and allowed access to food and water ad libitum. All experimental procedures were approved by the Animal Ethics Committee of Shantou University Medical College (People's Republic of China).
Adeno-associated virus vector production
AAV2 and AAV5 vectors containing the same genome were constructed. The EGFP cDNA under the control of the synapsin-1 gene promoter was cloned into a plasmid containing inverted terminal repeats from the AAV serotype 2. The plasmid was packaged into the capsids of either AAV2 or AAV5. Infectious titers of both the AAV vectors were 2.8 Â 10 8 TU/ml.
Surgical procedures
For surgery, mice were deeply anaesthetized using an intraperitoneal injection of ketamine and xylazine (125 mg of ketamine hydrochloride and 12.5 mg of xylazine per kilogram body weight). Three mice were used for each AAV serotype vector in each experiment, with three independent experiments being carried out in total. Surgery was performed as described by Apostolova et al. [16] , with minor modifications. In brief, a laminectomy was performed at T7-T9. The mouse spinal cord compression was performed by holding the spinal cord between a pair of tweezers (tweezer Dumont #5, World Precision Instrument, Sarasota, USA), closing the tweezers as quickly as possible and with a full compression lasting for 5 s. This procedure yields results that are as reproducible as those with the magnetic device used by Apostolova et al. [16] .
Immediately after injury, 1 ml of phosphate-buffered saline, pH 7.3, containing the viral constructs, AAV2 or AAV5, was injected slowly into the spinal cord 2 mm rostral and caudal to the lesion site. The injection and withdrawal of the syringe took approximately 5 min so as to avoid leaking back of the injected fluid. The muscle and skin were surgically closed separately using 6-0 stitches (Ethicon, Norderstedt, Germany).
To prevent hypothermia, the mice were maintained in a warm room (351C) for several hours after the operation [16] . Thereafter, they were singly housed under standard conditions with water and standard food provided ad libitum. During the postoperative period their bladders were manually voided twice daily.
Tissue preparation
Four weeks after spinal cord compression and AAV vector injection, the mice were transcardially perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.3 (4% PFA). A 3.6-cm long section of each spinal cord containing the injury site in the center was removed. The tissue was postfixed in 4% PFA at 41C overnight, kept in 20% sucrose at 41C for 1 day, embedded in optimal cutting temperature compound (Sakura Finetek, Torrance, USA), and snap frozen in 2-methyl-butane (isopentane) precooled to -701C. Twenty-five micrometer thick cross-sections were cut using a cryostat (CM1850, Leica, Nussloch, Germany).
Cell counting and fluorescence intensity measurement
Serial cross-sections spaced 400-mm apart were collected on a glass slide. For each animal, one series of sections was stained with 4 0 ,6-diamidino-2-phenylindole and the cells positive for EGFP were counted according to the Optical Fractionator method (MicroBright-Field, Magdeburg, Germany). An epifluorescence microscope (Axio Image Z1, Zeiss, Oberkochen, Germany) that was equipped with a motorized stage and a Stereo Investigator softwarecontrolled computer system (MicroBright-Field) was used for quantitative analysis. For quantitative EGFP fluorescence intensity evaluation, the NIH software ImageJ (http://rsbweb.nih.gov/ij/index.html) was used.
Data acquisition and statistical analysis
All tests were performed and analysed in a blinded manner. Student's t-test, for independent samples, was used to compare the groups. Throughout the text and in the figures, data are presented as means with standard error of the mean. 
Results
Maximum diffusion distance of AAV vectors from the injection site
With EGFP as a reporter gene, we first analysed the diffusion distance of the AAV2 and AAV5 vectors away from the injection sites. In serially spaced cross-sections, EGFP-positive sections furthest from the injury site rostrally and caudally were recorded. The distance of these sections from the injury site minus 2 mm (distance of the injection site from the injury site) is shown as the maximum diffusion distance. Determination of the maximum diffusion distance of each AAV vector (Fig. 1) in the injured spinal cord showed that AAV5 (6.9 ± 0.41 mm) had a significantly higher diffusion capacity than AAV2 (3.5 ± 0.61 mm, P = 0.001).
Distribution of AAV vectors in the injured spinal cord of mice
To further characterize the diffusion and transduction capacity of AAV2 and AAV5, the distribution profile of EGFP ( Fig. 2a ) was determined. The distribution profile consisted of the fluorescence intensity of EGFP for each serially spaced cross-section. The sections with the site of injury, site of injection, site of maximum EGFP labelling intensity and site of the furthest diffusion distance of EGFP expression were recorded ( Fig. 2b-i) .
The sections at the injury site showed dense 4 0 ,6diamidino-2-phenylindole staining with little EGFP expression ( Fig. 2b, f) , indicating that a dense cellular core had formed at the injury site [15] that was due to the infiltration of meningeal, vascular endothelial and immune system-derived cells, which do not express synapsin-1 and therefore do not activate the promoter of this gene for EGFP expression.
At the site of injection, which was 2 mm from the site of injury (Fig. 2c, g) , sections from the AAV5-injected mice showed a larger area of EGFP expression ( Fig. 2g ) compared with AAV2. However, owing to the limited diffusion of AAV2, the viral particles accumulated at the site of injection. On analysing the expression profile, the average fluorescence intensity was higher for AAV2 at the site of injection compared with AAV5 ( Fig. 2a ).
The site of maximum EGFP labelling intensity (Fig. 2d , h) and the furthest diffusion distance ( Fig. 2e, i) , observed for the AAV5-injected animals (5.2 mm and 9.6 mm, respectively) were seen at a greater distance than those seen for the AAV2-injected animals (2.8 mm and 6.8 mm, respectively). Thus, AAV5 diffused more extensively along the spinal cord with peaks of EGFP fluorescence intensity being higher and further away from the site of injection than AAV2.
Transduction efficiency of AAV vectors in the injured spinal cord
The transduction efficiency of the AAV vectors can be divided into two aspects: the number of cells that are transduced with the AAV vectors and the level of protein expression of the tested gene, considering that several transduction events could occur in one cell.
An unbiased stereological estimation of the number of EGFP-positive cells (Fig. 3a ) was used to determine the number of cells that were transduced with AAV vectors.
AAV5 transduced a significantly higher number of cells (198 792 ± 17 736) in the injured spinal cord, being approximately two-fold higher than those transduced with AAV2 (98 171 ± 3191, P = 0.005).
The expression level of the EGFP reporter gene can be determined by its fluorescence intensity. The total fluorescence intensity of EGFP in serial cross-sections spaced 400-mm apart along the 3.6-cm long spinal cord tissue was measured. In the AAV5-injected spinal cords, EGFP expression was approximately three-fold higher (100 ± 4.31%) than in the AAV2-injected ones (29.6 ± 3.85%, P < 0.001) (Fig. 3b ). This indicates that AAV5 yields a more potent gene expression than AAV2 in the injured spinal cord.
Discussion
Traumatic spinal cord injury immediately leads to irreversible primary injury. At the injury site, blood vessels are damaged, axons disrupted, astrocytes and microglia are activated and immune system cells infiltrate into the lesioned tissue. Haemorrhages occur rapidly and spread axially [17] . Subsequently, alterations in the local ion concentrations [18] , production of free radicals [19] and release of cytotoxic neurotransmitters [20] contribute to the damage of healthy neighbouring cells. In the chronic phases, the spinal cord sustains major tissue loss with often large cavitations, and sites rostral and caudal to the lesion show well-demarcated necrotic areas [21] , indicating extensive damage at and further away from the lesion site. Thus, using AAV gene therapy, vectors with high-diffusion capacity and potent transduction and expression efficiencies promise to be an effective treatment once the virus codes for expression of a regeneration-conducive molecule.
In this study, we used a spinal cord compression model in mice to mimic a form of traumatic spinal cord injury relevant to injuries in the human. The AAV capsids of AAV2 and AAV5, containing the same genome and titer of infectious units, were used to compare the diffusion capacity as well as the transduction and expression efficiencies.
In previous studies, the transduction by AAV2 in the brain [22] or other tissues [13] led to gene expression being confined to the injection site, whereas AAV5 was dispersed over a larger area [22] . However, when comparing the AAV2 and AAV5 expressions in the uninjured spinal cord of the rat, AAV5 was not found to be statistically more effective than AAV2 for, both, the number of cells transduced and the transduction volume [23] . In this study, examining the injured mouse spinal cord, AAV5 had a significantly higher diffusion capacity and a higher number of transduced cells compared with AAV2.
With the genes within the AAV2 and AAV5 capsids being identical, gene delivery by AAV5 yielded significantly higher EGFP expression compared with AAV2. The capsid is not only important for the vector to bind and enter the target cells, but is also important for postentry steps, such as the pathways involved in cellular processing, intracellular transit, nuclear entry, and vector genome processing [24] . For instance, AAV5-transduced retinas contained 30-fold more genome copies per cell than those transduced with AAV2 [25] . Similarly, our results indicate that the AAV5 capsids have increased expression of the target gene in the injured spinal cord compared with the AAV2 capsids.
Conclusion
Vectors with high-diffusion capacity and transduction efficiency are required for potential therapy after spinal cord injury or other types of acute and chronic trauma to the CNS of mammals. In this study, the spinal cord compression model in the mouse provided a traumatic environment to probe for the two most commonly used AAV vectors. We demonstrate that AAV5 is a more effective option after spinal cord injury and possibly also in other conditions of traumatic injury because of its higher diffusion capacity as well as transduction and expression efficiencies.
